RxDoctor Payments Data

Vidya Reddy, MD

Internal Medicine · Brooklyn, NYNPI 1609875533

Payments from drug & device makers

$568in general payments, 2019–2025

Across 30 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$173
  • Amarin Pharma, Inc.$72
  • Amgen$62
  • Merck$56
  • Bayer$49
  • Astellas Pharma US Inc$39
  • plus $118 from 4 others

What the payments were for

  • Food & beverage$54997%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$568 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$223,347
Medicare patients
119
Services billed
2,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate88$105,799
JardianceEmpagliflozin74$95,169
OzempicSemaglutide45$79,818
XareltoRivaroxaban38$45,843
EliquisApixaban45$43,866
TrulicityDulaglutide21$39,395
JanumetSitagliptin Phos/Metformin Hcl35$36,599
FarxigaDapagliflozin Propanediol31$31,944
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog46$29,238
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,523
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$9,405
Novolog FlexpenInsulin Aspart25$7,882
Breo ElliptaFluticasone/Vilanterol12$7,017
Enalapril Maleate248$6,645
Atorvastatin Calcium608$6,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$56$142,398123 claims
AstraZenecaFarxiga, Breztri Aerosphere$173$46,46854 claims
Lilly USA, LLCTrulicity$32$39,39521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →